Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.

  title={Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.},
  author={Philip C. Caron and Larry J. Dumont and David A. Scheinberg},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={4 6},
Humanized anti-CD33 monoclonal antibody HuM195 specifically targets myeloid leukemias in vivo and has been shown to produce molecular remissions in patients with acute promyelocytic leukemia who are in clinical remission. Previous human trials have used low intermittent dosing of HuM195 at 3 mg/m2/day, which is adequate to saturate all available CD33 sites in vivo. In the current trial, we investigated supersaturating doses of HuM195. Ten patients with relapsed or refractory myelogenous… CONTINUE READING
33 Citations
28 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 33 extracted citations


Publications referenced by this paper.
Showing 1-10 of 28 references

A Phase LB trial of humanized monclonab antibody Ml95 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity

  • P. C. Caron, J. C. Jurcic, +9 authors D. A. Scheinberg
  • Blood
  • 1994
Highly Influential
10 Excerpts

Radioimmunotherapy of Myeloid Leukemias with Anti-CD33 Based Agents

  • D. A. Scheinberg, J. G. Jurcic, +5 authors G. Sgouros
  • Proceedings of the Sixth Conference on…
  • 1996
1 Excerpt

Similar Papers

Loading similar papers…